Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1245.50
-24.30 (-1.91%)
< Home < Back

Dr. Reddy's launches Aspirin, Dipyridamole Capsules in US Market

Date: 24-12-2018

Dr. Reddy's Laboratories has launched Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) Capsules in the United States (US) market from the U.S. Food and Drug Administration (USFDA).

The Aggrenox brand and generic had U.S. sales of approximately $182 million MAT for the most recent twelve months ending in October 2018, according to IMS Health. Dr. Reddy's Aspirin and Extended-Release Dipyridamole Capsules is available in 25 mg/200 mg strength with 60 count bottle size. Aggrenox is a trademark of Boehringer lngelheim.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.